(Q41585407)

4 October 2017

title

Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors (English)

1 reference

4 October 2017

1 reference

Lehmann DF

1

1 reference

4 October 2017

Hurteau TE

series ordinal

2

1 reference

4 October 2017

Newman N

series ordinal

3

1 reference

4 October 2017

Coyle TE

series ordinal

4

1 reference

4 October 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

Clinical Pharmacology & Therapeutics

4 October 2017

published in

1 reference

4 October 2017

volume

62

1 reference

4 October 2017

issue

2

1 reference

4 October 2017

page(s)

225-229

1 reference

Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

4 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Twenty years of MOPP therapy for Hodgkin's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Cytochrome P-450- and peroxidase-dependent activation of procarbazine and iproniazid in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Drug-protein conjugation and its immunological consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Recent advances: the cytochrome P450 enzymes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Increased teniposide clearance with concomitant anticonvulsant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

Metabolism of hydrazine anti-cancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

7 January 2021

New antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990071-0

10.1016/S0009-9236(97)90071-0

7 January 2021

Identifiers

DOI

1 reference

4 October 2017

1 reference